Q-omics provides the consensus-scored PGBD5 profile across patient tissues and cancer cell-line models. PGBD5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, PGBD5 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, PGBD5 RNA expression shows 18,103 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight THCA, KIRP, and ACC as cancer lineages where PGBD5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PGBD5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PGBD5 survival associations across molecular data types. PGBD5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PGBD5 RNA expression–survival associations across cancer types. High PGBD5 expression shows unfavorable associations in THCA, KIRP, BRCA, ACC and UVM, but favorable associations in PAAD. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for PGBD5 RNA expression.
This table summarizes PGBD5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PGBD5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PGBD5 shows lower tumor expression in KICH and higher tumor expression in KIRP, KIRC, HNSC, LIHC and LUSC. The KIRP box plot shows higher PGBD5 RNA expression in tumor versus normal tissue (log2 FC = +1.863, t-test p < 0.001).
This table shows molecular features associated with PGBD5 in patient tissues and cancer cell lines. In patient samples, PGBD5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PGBD5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
